The FDA granted breakthrough therapy designation to DT120 Orally Disintegrating Tablet for the treatment of major depressive disorder based on preliminary clinical evidence.
Agree
Disagree
Overview
Debates
Related claims
Topics
Sources
From the article
FDA grants breakthrough therapy designation for DT120 ODT in depression treatment
5
52c7ae14
Article
FDA grants breakthrough therapy designation for DT120 ODT in depression treatment
0